Skip to main content

Advertisement

Table 1 Demographic, serological, clinical data and medication of patients treated with MMF or CYC compared to controls

From: Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus

Demographic, serological, clinical data and medication MMF CYC Controls
(number = 25) (number = 20) (number = 22)
SLEDAI-2 k (points); median (range) 8 (2 to 14) 11 (0 to 16) 9 (3 to 18)
gender female number (%) 18 (72.0) 14 (70.0) 18 (81.8)
age (years); mean ± SD 38 ± 13 34 ± 9 40 ± 14
duration (years); median (range) 9 (2 to 28)a 4 (0 to 25)a 10 (0 to 26)
age at initial diagnosis of SLE (years); mean ± SD 27 ± 11 29 ± 10 29 ± 14
medication  
prednisone (mg/day); median (range) 7.0 (2.5 to 15.0) 10.0 (0.0 to 30.0) 6.3 (0.0 to 100.0)
co-medication with antimalarials number (%) 18 (72.0) 12 (60.0) 16 (72.7)
currently active manifestations number (%)  
class III-V nephritis 10 (40.0) 12 (60.0) 6 (27.3)
eGFR <60 ml/min 7 (28.0) 4 (20.0) 3 (13.6)
C3c <0.9 g/L 18 (72.0) 14 (70.0) 16 (72.7)
neuropsychiatric 0 0 0
mucocutaneous/cutaneous 8 (32.0) 8 (40.0) 7 (31.8)
arthritis 5 (20.0) 0bb 9 (40.9)bb
serositis 1 (4.0) 0 4 (18.2)
myositis 1 (4.0) 1 (5.0) 1 (4.5)
autoantibodies number (%)  
anti-dsDNA >7 U/ml 21 (84.0) 15 (75.0) 20 (90.9)
anti-Ro >7 U/ml 11 (44.0) 10 (50.0) 13 (59.1)
anti-La >7 U/ml 4 (16.0) 4 (20.0) 4 (18.2)
anti-U1-RNP >5 U/ml 11 (44.0) 12 (60.0) 8 (36.4)
anti-SM >5 U/ml 7 (28.0) 9 (45.0) 4 (18.2)
  1. Statistically significant differences (Dunn’s multiple comparisons test or Fisher’s exact test) were observed between patients receiving MMF and CYC (a) and patients receiving CYC versus controls (b) one (P <0.05), two (P <0.01) symbols ab. C3c: complement factor C3c, controls: patients with SLE not receiving MMF or CYC; CYC: cyclophosphamide; eGFR: estimated glomerular filtration rate; MMF: mycophenolate mofetil; SLE: systemic lupus erythematosus; SLEDAI-2 k: SLE disease activity index.